Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization

Launched by THE SECOND HOSPITAL OF SHANDONG UNIVERSITY · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a natural supplement called salidroside on pregnancy outcomes for women aged 35 to 40 who are undergoing in vitro fertilization (IVF). The aim is to see if salidroside can help improve the chances of a successful pregnancy, especially for those who have had difficulty producing enough eggs (a condition known as poor ovarian response). Participants will be divided into two groups: one will receive salidroside while the other will not, allowing researchers to compare the results.

To be eligible for the trial, women must be between 35 and 40 years old and undergoing their first or second cycle of IVF. They should have a history of low egg production, which will be determined by specific medical tests. Unfortunately, women with certain health issues, such as bleeding disorders or previous serious pregnancy complications, will not be able to participate. If you join the trial, you can expect close monitoring during your IVF cycle, and the study aims to provide valuable information that could help improve fertility treatments for women of advanced childbearing age.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥35 and \< 40 years old
• • 2. For the first or second cycle of IVF, ICSI or IVF with donor sperm
• • 3. According to the 2016 Poseton criteria for poor prognosis: the number of oocytes obtained in the previous routine ovulation induction protocol was 1-9, or AFC \< 5 or AMH \< 1.2ng/ml (measured within the past half year) in both ovaries.
• Exclusion Criteria:
• • 1. Patients with coagulation disorders
• • 2. Patients with previous abnormal uterine bleeding
• • 3. Combined with hydrosalpinx confirmed by B-ultrasound and HSG
• • 4. Uterine malformation (unicornuate uterus, septate uterus) or history of intrauterine adhesions
• • 5. Patients with previous spontaneous abortion ≥3 times
• • 6. Patients with contraindications to assisted reproductive technology or pregnancy
• • 7. Previous or current oral medication containing salidroside
• • 8. The controlled ovarian stimulation protocol included PPOS protocol, luteal phase ovulation induction protocol, and continuous stimulation protocol